PDCD1 and neoplasm: Other approaches such as monoclonal antibody therapy against CXCR2 (Highfill et al., 2014), CCL2 (Wang et al., 2018), or IL-18 (Guan et al., 2017) to inhibit MDSCs trafficking into tumors also successfully induces tumor regression upon anti-PD1 treatment.